|Table of Contents|

Progress in therapeutic evaluation of breast cancer receiving neoadjuvant chemotherapy by imaging analysis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 04
Page:
740-744
Research Field:
Publishing date:

Info

Title:
Progress in therapeutic evaluation of breast cancer receiving neoadjuvant chemotherapy by imaging analysis
Author(s):
LI Yingpu; PANG Da
Department of Breast Surgery,Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150000,China.
Keywords:
breast cancer; mammography; ultrasound; MRI; neoadjuvant chemotherapy
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2022.04.040
Abstract:
Neoadjuvant chemotherapy (NAC) is a presurgical treatment for the purpose of tumor down-staging and breast conservation,with the aim to transform patients from inoperable to operable.While patients who need mastectomy may instead of breast conservation surgery.For patients suffered from lymph node metastasis,there exists a potential that axillary lymph node metastasis treated with NAC achieving pathological complete response (pCR) may avoid possible unnecessary axillary lymph node dissection.Therefore,the prognosis of patients is associated with the therapeutic effect of the preoperative assessment.MRI and contrast-enhancement ultrasound have the ability to accurately measure the size of lesions after receiving NAC independent to states of pCR or axillary lymph node metastasis.These techniques could provide important information of patients and contribute to the selection of optimized treatment plans and prognosis.This article reviews the literatures about the imaging analysis of breast cancer patients after NAC.

References:

[1] WINTERS S,MARTIN C,MURPHY D,et al.Breast cancer epidemiology,prevention,and screening［J］.Prog Mol Biol Transl Sci,2017,151：1-32.
[2] MIGLIETTA F,DIECI MV,GRIGUOLO G,et al.Neoadjuvant approach as a platform for treatment personalization:focus on HER2-positive and triple-negative breast cancer［J］.Cancer Treat Rev,2021,98：102222.
[3] WOO J,RYU JM,JUNG SM,et al.Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer［J］.Eur J Surg Oncol,2021,47(2):232-239.
[4] SWARNKAR PK,TAYEH S,MICHELL MJ,et al.The evolving role of marked lymph node biopsy (MLNB) and targeted axillary dissection (TAD) after neoadjuvant chemotherapy (NACT) for node-positive breast cancer:Systematic review and pooled analysis［J］.Cancers (Basel),2021,13(7)：1539.
[5] TAYDAS O,DURHAN G,AKPINAR MG,et al.Comparison of MRI and US in tumor size evaluation of breast cancer patients receiving neoadjuvant chemotherapy［J］.Eur J Breast Health,2019,15(2):119-124.
[6] LEE HB,HAN W,KIM SY,et al.Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings:a prospective feasibility trial［J］.Breast Cancer Res Treat,2020,182(1):97-105.
[7] MANN RM,CHO N,MOY L.Breast MRI:State of the art［J］.Radiology,2019,292(3):520-536.
[8] SCHEEL JR,KIM E,PARTRIDGE SC,et al.MRI,clinical examination,and mammography for preoperative assessment of residual disease and pathologic complete response after neoadjuvant chemotherapy for breast cancer:ACRIN 6657 trial［J］.AJR Am J Roentgenol,2018,210(6):1376-1385.
[9] KIM SY,CHO N,SHIN SU,et al.Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer:lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour［J］.Eur Radiol,2018,28(7):2986-2995.
[10] CHOI WJ,KIM HH,CHA JH,et al.Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients:Factors of radiologic-pathologic discordance［J］.Eur J Radiol,2019,118：114-121.
[11] HARADA TL,UEMATSU T,NAKASHIMA K,et al.Evaluation of breast edema findings at T2-weighted breast MRI is useful for diagnosing occult inflammatory breast cancer and can predict prognosis after neoadjuvant chemotherapy［J］.Radiology,2021,299(1):53-62.
[12] PALSHOF FK,LANNG C,KROMAN N,et al.Prediction of pathologic complete response in breast cancer patients comparing magnetic resonance imaging with ultrasound in neoadjuvant setting［J］.Ann Surg Oncol,2021,28:7421-7429.
[13] WU WP,WU HK,CHEN CJ,et al.Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)-A concordance comparison cohort analysis［J］.PLoS One,2019,14(10):e0222917.
[14] KIM Y,KIM SH,SONG BJ,et al.Early prediction of response to neoadjuvant chemotherapy using dynamic contrast-enhanced MRI and ultrasound in breast cancer［J］.Korean J Radiol,2018,19(4):682-691.
[15] KIM SY,CHO N,PARK IA,et al.Dynamic contrast-enhanced breast MRI for evaluating residual tumor size after neoadjuvant chemotherapy［J］.Radiology,2018,289(2):327-334.
[16] LI W,NEWITT DC,GIBBS J,et al.Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI:results from the I-SPY2 TRIAL［J］.NPJ Breast Cancer,2020,6(1):63.
[17] MONTEMEZZI S,BENETTI G,BISIGHIN MV,et al.3T DCE-MRI radiomics improves predictive models of complete response to neoadjuvant chemotherapy in breast cancer［J］.Front Oncol,2021,11：630780.
[18] JARRETT AM,HORMUTH DA,WU C,et al.Evaluating patient-specific neoadjuvant regimens for breast cancer via a mathematical model constrained by quantitative magnetic resonance imaging data［J］.Neoplasia,2020,22(12):820-830.
[19] PETERS NH,BOREL RINKES IH,ZUITHOFF NP,et al.Meta-analysis of MR imaging in the diagnosis of breast lesions［J］.Radiology,2008,246(1):116-124.
[20] PARTRIDGE SC,ZHANG Z,NEWITT DC,et al.Diffusion-weighted MRI findings predict pathologic response in neoadjuvant treatment of breast cancer:The ACRIN 6698 multicenter trial［J］.Radiology,2018,289(3):618-627.
[21] NEWITT DC,ZHANG Z,GIBBS JE,et al.Test-retest repeatability and reproducibility of ADC measures by breast DWI:Results from the ACRIN 6698 trial［J］.J Magn Reson Imaging,2019,49(6):1617-1628.
[22] TOKUNAGA R,NASEEM M,LO JH,et al.B cell and B cell-related pathways for novel cancer treatments［J］.Cancer Treat Rev,2019,73：10-19.
[23] LECUN Y,BENGIO Y,HINTON G.Deep learning［J］.Nature,2015,521(7553):436-444.
[24] MEYER-BASE A,MORRA L,TAHMASSEBI A,et al.AI-enhanced diagnosis of challenging lesions in breast MRI:A methodology and application primer［J/OL］.J Magn Reson Imaging,2020［2020-08-31］.https://doi.org/10.1002/jmri.27332.
[25] GILLIES RJ,KINAHAN PE,HRICAK H.Radiomics:Images are more than pictures,they are data［J］.Radiology,2016,278(2):563-577.
[26] MANI S,CHEN Y,LI X,et al.Machine learning for predicting the response of breast cancer to neoadjuvant chemotherapy［J］.J Am Med Inform Assoc,2013,20(4):688-695.
[27] LIU Z,LI Z,QU J,et al.Radiomics of multiparametric MRI for pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer:A multicenter study［J］.Clin Cancer Res,2019,25(12):3538-3547.
[28] TAHMASSEBI A,WENGERT GJ,HELBICH TH,et al.Impact of machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy and survival outcomes in breast cancer patients［J］.Invest Radiol,2019,54(2):110-117.
[29] TSUKADA H,TSUKADA J,SCHRADING S,et al.Accuracy of multi-parametric breast MR imaging for predicting pathological complete response of operable breast cancer prior to neoadjuvant systemic therapy［J］.Magn Reson Imaging,2019,62:242-248.
[30] XIONG Q,ZHOU X,LIU Z,et al.Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy［J］.Clin Transl Oncol,2020,22(1):50-59.
[31] SANTAMARIA G,BARGALLO X,GANAU S,et al.Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes:Comparison between different definitions of pathologic complete response［J］.Eur J Radiol,2019,117:132-139.
[32] GIULIANO AE,BALLMAN KV,MCCALL L,et al.Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis:The ACOSOG Z0011 (Alliance) Randomized Clinical Trial［J］.JAMA,2017,318(10):918-926.
[33] MATTAR D,DI FILIPPO A,INVENTO A,et al.Economic implications of ACOSOG Z0011 trial application into clinical practice at the European Institute of Oncology［J］.Eur J Surg Oncol,2021［2021-06-27］.https://www.researchgate.net/publication/352364595_Economic_implications_of_ACOSOG_Z0011_trial_application_into_clinical_practice_at_the_European_Institute_of_Oncology.DOI:10.1016/j.ejso.2021.06.016.
[34] SAMIEI S,DE MOOIJ CM,LOBBES MBI,et al.Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer:A systematic review and Meta-analysis［J］.Ann Surg,2021,273(4):694-700.
[35] ZHANG X,WANG D,LIU Z,et al.The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer［J］.Quant Imaging Med Surg,2020,10(1):197-210.
[36] GRADISHAR WJ,MORAN MS,ABRAHAM J,et al.NCCN guidelines(R) insights:Breast cancer,version 4.2021［J］.J Natl Compr Canc Netw,2021,19(5):484-493.
[37] ALMEREY T,VILLACRESES D,LI Z,et al.Value of axillary ultrasound after negative axillary MRI for evaluating nodal status in high-risk breast cancer［J］.J Am Coll Surg,2019,228(5):792-797.
[38] KIM R,CHANG JM,LEE HB,et al.Predicting axillary response to neoadjuvant chemotherapy:Breast MRI and US in patients with node-positive breast cancer［J］.Radiology,2019,293(1):49-57.
[39] EUN NL,SON EJ,GWEON HM,et al.Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients［J］.Eur Radiol,2020,30(3):1460-1469.
[40] MORGAN C,STRINGFELLOW TD,ROLPH R,et al.Neoadjuvant chemotherapy in patients with breast cancer:Does response in the breast predict axillary node response［J］.Eur J Surg Oncol,2020,46(4 Pt A):522-526.
[41] BOCA BENE I,DUDEA SM,CIUREA AI.Contrast-enhanced ultrasonography in the diagnosis and treatment modulation of breast cancer［J］.J Pers Med,2021,11(2):81.
[42] SARACCO A,SZABO BK,TANCZOS E,et al.Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy［J］.Acta Radiol,2017,58(4):394-402.
[43] CAO X,XUE J,ZHAO B.Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer［J］.Ultrasound Med Biol,2012,38(12):2065-2071.
[44] COX K,DINEEN N,TAYLOR-PHILLIPS S,et al.Enhanced axillary assessment using intradermally injected microbubbles and contrast-enhanced ultrasound (CEUS) before neoadjuvant systemic therapy (NACT) identifies axillary disease missed by conventional B-mode ultrasound that may be clinically relevant［J］.Breast Cancer Res Treat,2021,185(2):413-422.
[45] WU X,TANG L,HUANG W,et al.Contrast-enhanced ultrasonography and blue dye methods in detection of sentinel lymph nodes following neoadjuvant chemotherapy in initially node positive breast cancer［J］.Arch Gynecol Obstet,2020,302(3):685-692.

[46] LEE SC,GRANT E,SHETH P,et al.Accuracy of contrast-enhanced ultrasound compared with magnetic resonance imaging in assessing the tumor response after neoadjuvant chemotherapy for breast cancer［J］.J Ultrasound Med,2017,36(5):901-911.
[47] ABDELHAFEZ AH,MUSALL BC,ADRADA BE,et al.Tumor necrosis by pretreatment breast MRI:association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)［J］.Breast Cancer Res Treat,2021,185(1):1-12.

Memo

Memo:
-
Last Update: 1900-01-01